Stem-Cell Therapy for ED
Adipose- vs Bone-Marrow-Derived Cells, the Haahr Pilots, FDA Warning Letters, and Stem-Cell Tourism
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No approved stem-cell product for ED; FDA warning letters and a permanent injunction against a major clinic
Reference only. Not medical advice.
What can go wrong
Autologous cell injection carries infection, bleeding, and, with adipose processing, the regulatory reality that many products are unapproved drugs. The predatory sector has documented serious harm (infections, and in a non-genital stem-cell case, blindness). Financial harm is substantial: unproven treatment often costs many thousands of dollars, and stem-cell tourism adds travel to jurisdictions with weaker oversight.
This is something to take to a clinician. The Atlas can tell you what is known about stem-cell therapy for ed in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Stem-cell therapy for ED involves injecting cells, most commonly adipose-derived regenerative cells / stromal vascular fraction, or bone-marrow-derived mesenchymal stem cells, into the corpora cavernosa to promote angiogenesis, endothelial repair, and nerve recovery. The legitimate human evidence is a set of small open-label phase-I pilots, notably Trost/Haahr and colleagues' work in post-prostatectomy men (Haahr et al., EBioMedicine 2016, and a 12-month follow-up in Urology), which found the injections safe and reported erectile-function improvement in a subset of continent men. There is no pivotal RCT and no FDA-approved stem-cell product for ED. Alongside this research sits a predatory, unregulated clinic industry marketing 'stem cell' ED cures; the FDA has issued warning letters and, in US v. US Stem Cell Clinic, obtained a 2019 permanent injunction after a court found the clinic adulterated and misbranded adipose-derived products. Stem-cell tourism sends patients abroad for the same unproven treatments.
Legitimate early research shadowed by a predatory, sometimes unlawful clinic industry.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Injected mesenchymal or adipose-derived stem cells are hypothesized to act mainly through paracrine signaling, secreting growth factors and cytokines (VEGF, and via exosomes) that promote angiogenesis, protect and repair cavernosal endothelium and nerves, and reduce fibrosis, rather than by engrafting and becoming new tissue. In animal models of diabetic and post-cavernous-nerve-injury ED the effect is reproducible; translating it to durable human benefit is the unsolved step.
The catch: pilots are not proof, and the marketplace is largely unlawful
The human data are phase-I: small, open-label, uncontrolled, designed to test safety, not efficacy. The Haahr group's post-prostatectomy pilots reported improvement in a subset (roughly half of continent men) but had no placebo arm, so placebo and regression-to-the-mean cannot be excluded. Meanwhile a large commercial industry sells 'stem cell' ED treatment outside any trial. The FDA has issued warning letters to clinics, and in US v. US Stem Cell Clinic a federal court (S.D. Fla., June 2019) granted a permanent injunction after finding the clinic's adipose-derived stromal vascular fraction products adulterated and misbranded; that clinic's non-genital procedures had blinded patients. The same product marketed for ED carries the same regulatory and safety problems.
What people get wrong
Often saidStem cells are a proven ED cure
ActuallyThe only legitimate human data are small uncontrolled safety pilots. There is no pivotal RCT and no FDA-approved stem-cell product for ED.
Often saidClinics offering 'stem cell' ED therapy are FDA-approved
ActuallyMany operate outside the law; the FDA has issued warning letters and won a permanent injunction against a prominent clinic.
Often saidGoing abroad gets you the 'real' treatment
ActuallyStem-cell tourism typically delivers the same unproven therapy with less oversight and greater risk.
Who profits, and who pushes back
FDA / US Department of Justice
The clinic's adipose-derived cell products were adulterated and misbranded drugs marketed without approval.
International Society for Stem Cell Research
Applauded the ruling; unproven stem-cell treatments marketed directly to patients are a public-health concern.
In the legitimate lane, funding is academic and grant-based. In the commercial lane, revenue flows to clinics charging five figures cash and to medical-tourism intermediaries, selling an unapproved procedure as a cure.
What we do not know
- Can a placebo-controlled trial confirm the subset benefit seen in the post-prostatectomy pilots?
- Is the mechanism paracrine (favoring a cell-free product) rather than engraftment?
- Will enforcement keep pace with the commercial clinic industry?
At a glance
- Legitimate evidence
- Small phase-I pilots (Haahr), no pivotal RCT
- Cell types
- Adipose-derived (SVF) vs bone-marrow MSCs
- FDA product for ED
- None approved
- Landmark enforcement
- US v. US Stem Cell Clinic, injunction 2019
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Stem-Cell Therapy for ED. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Haahr et al., EBioMedicine, autologous adipose-derived regenerative cells after radical prostatectomy2016
Open-label phase-I, n=17; safe, with erectile-function improvement in a subset of continent men
Haahr et al., 12-month follow-up (Urology)2018
Single injection followed to 12 months; favorable safety, ~half of continent patients showing improvement, still uncontrolled
US v. US Stem Cell Clinic (S.D. Fla.) permanent injunction2019
Court found adipose-derived (SVF) products adulterated and misbranded; landmark FDA enforcement affirming jurisdiction over such 'stem cell' products